Showing results (81-90 of 126) with videos related to
Sort By:
Pageof 13
Blood Advances|December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA groupRaphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.Blood|July 30, 2025
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid MalignanciesTraci L Kruer, Ariel Quintana-Gonzalez, Hannah L Newman, et al.The Lancet. Haematology|July 22, 2024
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, et al.Blood Advances|May 8, 2020
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study resultsClaude Gardin, Cécile Pautas, Elise Fournier, et al.British Journal of Haematology|October 3, 2023
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT studyFrédéric Baron, Arnon Nagler, Jacques-Emmanuel Galimard, et al.British Journal of Haematology|July 14, 2018
Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des MyélodysplasiesLouis Drevon, Alice Marceau, Odile Maarek, et al.Blood Advances|October 8, 2025
Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availabilityMarie Sebert, Sylvain Thepot, Thomas Cluzeau, et al.British Journal of Haematology|June 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life studyThibault Comont, Mathieu Meunier, Amina Cherait, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.European Journal of Human Genetics : EJHG|October 3, 2025
Myeloid neoplasms risks for germline DDX41 pathogenic variants carriersMarie-Charlotte Villy, Youenn Drouet, Lise Larcher, et al.Pageof 13